FY2024 Earnings Forecast for Masimo Issued By Zacks Research

Masimo Co. (NASDAQ:MASI) – Equities researchers at Zacks Research issued their FY2024 EPS estimates for Masimo in a note issued to investors on Wednesday, February 19th. Zacks Research analyst I. Bandyopadhyay expects that the medical equipment provider will post earnings of $4.10 per share for the year. The consensus estimate for Masimo’s current full-year earnings is $4.10 per share. Zacks Research also issued estimates for Masimo’s Q4 2024 earnings at $1.49 EPS.

Several other brokerages also recently issued reports on MASI. Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a report on Wednesday, January 22nd. Stifel Nicolaus reaffirmed a “buy” rating and issued a $190.00 target price (up previously from $170.00) on shares of Masimo in a research report on Friday, November 22nd. Wells Fargo & Company raised their target price on Masimo from $171.00 to $193.00 and gave the company an “overweight” rating in a report on Wednesday, December 11th. Raymond James upped their price target on Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a report on Friday, December 27th. Finally, Piper Sandler increased their price objective on shares of Masimo from $180.00 to $210.00 and gave the company an “overweight” rating in a research report on Wednesday, December 18th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $191.40.

Masimo Price Performance

Masimo stock opened at $170.72 on Monday. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50. The firm has a market capitalization of $9.14 billion, a P/E ratio of 117.74 and a beta of 1.02. The firm has a fifty day moving average of $172.65 and a 200-day moving average of $152.54. Masimo has a 52-week low of $101.61 and a 52-week high of $184.51.

Institutional Investors Weigh In On Masimo

A number of hedge funds have recently bought and sold shares of the business. Smartleaf Asset Management LLC boosted its stake in shares of Masimo by 31.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 250 shares of the medical equipment provider’s stock valued at $42,000 after buying an additional 60 shares during the last quarter. EverSource Wealth Advisors LLC raised its holdings in Masimo by 40.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider’s stock valued at $37,000 after acquiring an additional 64 shares in the last quarter. Blue Trust Inc. boosted its stake in Masimo by 56.3% during the 4th quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider’s stock valued at $33,000 after acquiring an additional 71 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its holdings in Masimo by 0.8% during the 4th quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 9,815 shares of the medical equipment provider’s stock worth $1,622,000 after acquiring an additional 82 shares in the last quarter. Finally, Thrivent Financial for Lutherans increased its position in shares of Masimo by 0.8% in the 4th quarter. Thrivent Financial for Lutherans now owns 10,456 shares of the medical equipment provider’s stock worth $1,728,000 after purchasing an additional 83 shares during the last quarter. Institutional investors and hedge funds own 85.96% of the company’s stock.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.